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Abstract: H7 as a member of the recently identified viral membrane assembly proteins 
(VMAPs) plays a key role in poxvirus membrane biogenesis. Although the detailed 
manner of the poxvirus membrane biogenesis remains largely unclear, it is suggested that 
H7 works together with other VMAPs to facilitate the acquisition of membrane from the 
host’s endoplasmic reticulum (ER). In eukaryotes, phosphoinositides and their binding 
proteins have been known for their importance in membrane and protein trafficking. 
From our previous study, a phosphoinositide-binding site was identified on two regions 
of the H7 protein, including the C-terminal tail and a surface patch that is comprised of 
basic residues. Through lipid overlay and fluorescence polarization-based lipid binding 
assays, the binding of H7 with phosphoinositides, PI3P and PI4P, was confirmed. A 
model, in which a positively charged pocket for binding phosphoinositdes was formed by 
two regions interacting with each other and the C-terminal’s possible function serving as 
a switch, was proposed from the previous structure-function studies.  Yet due to the 
intrinsic nature, the 29 residues at the C-terminal tail were not visible in the published H7 
structure. In this study, we aim to solve the complete structure of H7 in complex with 
phosphoinositides PI3P, PI4P. Due to the lack of sequence homology of H7 to proteins 
outside the poxvirus family, the structure-function study of H7 with lipid can provide a 
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Poxvirus is a large family of viruses that can affect both human and animals. There are 
four genera of poxviruses that can contribute to human infectious: orthopoxvirus, parapoxvirus, 
yatapoxvirus, molluscipoxvirus (Condit, Moussatche, & Traktman, 2006). The symptoms of 
poxvirus infection normally involve skin nodules, formation of lesions or disseminated rash.  
Smallpox, which is under the orthopoxvius category, might be one of the best-known poxvirus-
related diseases. Although in 1979 the WHO had acclaimed its eradication through the vaccine 
campaign, pathogenic orthopoxviruses remain a dangerous threat to the public health. 
Orthopoxviruses include variola virus, monkey pox virus and vaccinia virus (VACV) In the U.S., 
routine smallpox immunization was discontinued in the early-1970s. As a result, the current U.S. 
population is highly susceptible to smallpox that may be re-introduced maliciously or 
accidentally. Our studies will provide important clues to the controlling mechanism for poxvirus 
host tropism and fundamental knowledge for further improving VACV-based vaccine vector for 
infectious diseases and cancer. 
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Vaccinia virus is a prototype of poxvirus. It was used as an active agent in the eradication 




I.1.1 Poxvirus Structure 
Poxvirus are enveloped, brick shaped virions that are normally 200 nm in diameters and 300 nm 
in length (Condit et al., 2006). 
 
 
Figure1.1 Poxviridae structure model (Swiss Institute of Bioinformatics) 
The extracellular enveloped virus (EEV) and intracellular mature virus (IMV) (Figure 1.1) are 
both infectious. Compared to IMV, the EEV form of the virus has an extra membrane outside 
which is the envelope. The poxvirus envelope at early stage is a single membrane lipid bilayer 
that is stabilized by a honeycomb lattice coating, which later on can be completely replaced by a 
paracrystalline coating with the development of the virion (Heuser, 2005). Within the envelope 
and membrane, there is a “dumbbell” shaped core, containing nucleic acid encased by the core 
wall. The lateral body, of which the function is not quite clear, occupies the space between the 




I.1.2 Poxvirus Genetics 
The poxvirus genome, normally ranging from 130 to 375 kb, is encased in the core of the 
virus (Condit et al., 2006). As a family of large cytoplasmic virus, one of the most unique and 
important features of poxvirus is that they replicate and transcribe their large, double stranded 
DNA genome in the cytoplasm instead of in the nucleus region of the infected cells. It is a rather 
complex and distinguishable process since all the enzymes needed for the replication and 
transcription have to be encoded completely in the cytoplasm of the host cell at the right time, in 
the right place. Specific sites whereas virus’s replication and transcription occurs in the cytoplasm 
are called “viral factories”. These “viral factories” are also sites where viral assembly happens 
following the viral genome replication. The machinery of this intricate process involves the viral 
genome’s interaction with the microtubules (MTs) and endoplasmic reticulum (ER) of the host 
cell in the beginning of viral invasion (Ward & Moss, 2001). 
I.1.3 Poxvirus Morphogenesis 
In general, poxvirus morphogenesis is a rather complicated process (Figure 1.2). As the 
phrase “cycle ” indicate, the end point is also a new beginning---the poxvirus life cycle starts with 
its two infectious forms of its final products, i.e. the mature virus (MV) and extracellular 
enveloped virus (EEV). 
MV and EEV are structurally, antigenically and functionally distinguishable.(McFadden, 
2005). Their membrane fusion with the host cell is the starting of the viral entry. The exact 
manner of the viral entry is not understood. Yet, it is clear that once the virus entered, both MV 
and EEV will release its genome-containing core to the infected cell’s cytoplasm.  Upon release 
of the core, an early viral transcriptional mechanism is to be function. This mechanism ensures 
that proteins that are crucial for the subsequent steps in the life cycle are synthesized right away 
in the infected cell’s cytoplasm. These early proteins will facilitate t1) the core “un-coating”; 2) 
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the release of the parental DNA; 3) viral DNA replication (McFadden, 2005; Roberts & Smith, 
2008). After all early preparations for the viral invasion is finished, the virus will express 




Figure1.2 Schematic of vaccine virus life cycle. (Schramm & Locker, 2005) 
The viral assembly starts with the formation of a unique open-ended membrane 
structure—crescent shaped membrane. This membrane serves as a scaffold for the later 
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assembling process. A spherical immature virion (IV) that lacks the viral genome appears next.. 
Only until the IVs take up the viral DNA, forms the first infectious form of the virus-----
intracellular mature virus, IMV.. Some of these newly formed IMVs stay at these sites while 
others travel outside of these ‘viral factories’. These IMVs ‘travellers’ move to a ‘transportation 
center’ or microtubule-organizing center. From there, a small percentage of IMVs are wrapped by 
membranes derived from the Golgi network or endosomes. When the transformation is done, a 
new name is given to this small percentage of IMVs-----intracellular enveloped virus (IEV).  IEV 
will then utilize or hijack the infected cell’s ‘transportation system’----microtubules and kinesin 
travel to cell’s surface (Ward & Moss, 2001). After arrive at the cell surface, the virus envelope 
forms by fusing its outer membrane with the host cell’s plasma membrane. The enveloped virus 
can stay or release to the medium through budding. The released enveloped virus is the other 
infectious form of poxvirus mentioned at the beginning of this section, called extracellular 
enveloped virus (EEV). To this step, the life cycle of poxvirus is completed (McFadden, 2005; 
Roberts & Smith, 2008). 
I.3 Phosphoinositides 
Phosphoinositides are phosphorylated phosphatidylinositol (PI). There are three 
phosphorylation sites on the inositol ring of PI, the hydroxyl-groups on the 3rd ,4th 5th positions of 
the inositol ring. Through reversible phosphorylation by different kinases, 7 different PIs are 
generated (Figure 1.3), PI3P, PI4P, PI5P, PI (3,4) P, PI (3,5) P, PI (4,5) P and PI (3,4,5) P (Di 
Paolo & De Camilli, 2006). The distribution of these 7 phosphoinositides in different subcellular 
membranes is distinct and therefore contents of phosphoinositides in membranes can be used to 





Figure1.3 Generation of seven phophoinositides from phosphatidylinositol (PtdIns)   
(Di Paolo & De Camilli, 2006) 
Although phosphatidylinositol only composes less than 15% of the total phospholipids in 
cells, they have a major impact on cell biology. Their phosphorylated forms—phosphoinositides, 
play important roles in mediating cell signaling pathways, membrane trafficking, plasma 
membrane-cytoskeleton interactions, etc. (Di Paolo & De Camilli, 2006). The physiological 
functions of phosphoinositides are largely determined by the inositol head group’s interaction 
with different PI kinases and phosphatases. The negatively charged inositol head groups can bind 
specific proteins through electrostatic interactions, this in turn, expands the functions of 
phosphoinositides in cells. 
I.4 Phosphoinositides Binding Proteins 
Effector proteins specifically bind with phosphoinositides through electrostatic 
interaction. They contain one of the following domains: PX (phox- homology), PH (plexkstrin 
homology), FYVE (Fab1p/YOTB/Vac1p/EEA1), ENTN (Espin N-terminal homology) (Lorizate 
& Krausslich, 2011). Among all the phosphoinositdes, PI3P normally binds with endosomal 
proteins like EEA1, Hrs and SARA that contain either PX or FYVE domains (Figure 
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1.4.Stenmark & Gillooly, 2001). Effector proteins harboring PH and ENTN domains are the 
primary PI4P binding modules and mostly found in the Golgi apparatus (Delang, Paeshuyse, & 
Neyts, 2012). The binding with phosphoinositides will induce conformational changes of these 





Figure 1.4 Schematic of PX domain bind with PI3P 






I.5 Protein Crystallization and X-ray Crystallography. 
Protein crystallization is a process of crystallizing the protein of interests. Gene cloning 
and protein engineering are almost always engaged to get the protein. Different protein 
purification techniques such as nickel affinity chromatography, HPLC, ion exchange etc. are 
utilized to purify the protein to a homogeneous status. After a highly purified and concentrated 
protein sample is obtained, the next step is to set the protein of interest for crystallization. Briefly, 
it is the process of testing out buffer conditions under which protein can be crystallized. There are 
normally three ways of preparing the crystal: hanging drop method, sitting drop method or micro-
dialysis. The sitting drop method is what we are using in the lab. After a protein crystal is 
obtained, crystal optimization and selenomethionione replacement are normally applied before 
setting the crystal for X-Ray crystallography (Wlodawer, Minor, Dauter, & Jaskolski, 2008). 
X-Ray crystallography it is used to study protein structure at the atomic level after the 
protein crystal is obtained. Figure 1.6 shows major steps involved in X-Ray crystallography. 
 
 
Figure 1.5 Workflow of Solving the Molecule Structure by X-Ray Crystallography. (wikipedia) 
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This complicated process can be briefly understood as, firstly using a high energy beam 
(X-Ray) to focus on the crystal (the subject), then a diffraction pattern of the crystal’s electrons 
will appear on a image plate (like shadows on the wall) and can be recorded. While this 
diffraction pattern contains useful information of all atoms in the crystal, it is not enough for 
deciphering the crystal structure. X-ray, like other electro-magnetic radiations, it has both particle 
and wave properties. The diffraction pattern only give information on its particle (amplitude) 
side, the wave side as being called phase is missing. This is the well-known phase problem in the 
X-ray crystallography. Thus at this point, selenomethionione or heavy metal replacement 
methods will be introduced to obtain information for solving the phase problem.  After obtaining 
the atoms information from both amplitude and phase side, the electron density map can be 
calculated and interpreted into an atomic model. A model of the protein structure will be build 
using computer programs. An R-factor, which represents the difference between the data and the 








Vaccinia virus (VACA) as a prototype of poxvirus has been actively studied over the last 
decades. Despite the tremendous success of the WHO-led small pox vaccine campaign using 
vaccnia virus as an active agent in the late 1970s and lots of continuous studies, the detailed 
mechanisms of vaccnia virus morphogenesis remains largely unclear.  
Taking a closer look into the VACA life cycle (section I.1.3), one might find nature’s 
perfect illustration on the philosophy---“less is more” and be amazed by how complicated and 
precise the life processes are carried out by such a simple structure. Indeed, as one simple 
structured and genetically unique virus that replicates and transcribes its whole genome in the 
cytoplasm of the infected cell, VACA has evolved lots of elegant strategies to manipulate its host 
cells in facilitating its “invasion” at all stages. For example, one of the ways the virus uses to 
enter the host cells is by mimicking the apoptotic host cells thus triggers endocytosis (Amara & 
Mercer, 2015); in terms of  facilitating the viral replication, the host cell’s innate immune 
pathways are suppressed through the virus induced up-regulation of  the anti-inflammatory 
cytokines (Liu et al., 2005) the heat shock response of the infected cells is shut off or differently 
regulated with the VACA infection (Liem & Liu, 2016); to ensure viral translation, the VACA 
hijacks the host cell’s translation machinery by manipulating the PI3P/AKT signaling pathway 
during the infection (Liem & Liu, 2016; McNulty et al., 2010), etc.
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With technological advances in molecular and structural biochemistry, people’s 
understanding of different molecular mechanisms involved in those strategies has been largely 
improved. Among all the aspects of the complicated VACA morphogenesis, the viral membrane 
biogenesis remains to be the least understood. Following the viral replication, the formation of an 
open-ended membrane structure---crescent membrane is the first step of the viral assembly 
process. The structure and origin of the crescent membrane has been a long debate among 
researchers over the last half-century. Contradictory theories (Dales S Fau - Mosbach & 
Mosbach, 1968; Higashi, Ozaki, & Ichimiya, 1960), in terms of the structure --- whether it is one 
membrane or two distinct layers, have been aroused. The controversy ended with the advances in 
the imaging techniques, confirming the crescent membrane is a single membrane of honeycomb 
lattice comprised of VACA D13 protein trimmers (Heuser, 2005; Szajner, Weisberg, Lebowitz, 
Heuser, & Moss, 2005). In view of the crescent membrane formation, rather than synthesized “de 
novo” (Dales S Fau - Mosbach & Mosbach, 1968), more evidence (Chlanda, Carbajal, Cyrklaff, 
Griffiths, & Krijnse-Locker, 2009; Husain, Weisberg As Fau - Moss, & Moss, 2006; Krijnse 
Locker, Chlanda, Sachsenheimer, & Brugger, 2013) support that the viral membrane is derived 
and ruptured from ER by a highly controlled mechanism. 
 In this highly controlled membrane biogenesis mechanism, several viral proteins have 
been identified for their crucial roles in the membrane formation. Essential structural proteins for 
crescent membrane formation are the scaffold protein D13 and the two major trans-membrane 
proteins A14 and A17 (Erlandson et al., 2016; Liu, Cooper, Howley, & Hayball, 2014). 
Regulatory proteins that are fundamental for viral membrane assembly are termed as viral 
membrane assembly proteins (VMAPs). 
Up to date, there are five identified VMAPs: A6, A11, A30.5, H7 and L2. Other than L2-
--the early-transcribed membrane protein that is co-localize with the ER throughout the whole 
replication process and is also found in the crescent membrane (Maruri-Avidal, Weisberg, & 
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Moss, 2011), the rest of VAMPs are exclusively expressed after the genome replication with 
different locations preference. Conditional lethal inducible and deletion mutants were applied in 
studying the roles of individual VMAPs. With pieces of information pulling together, models of 
VACA crescent membrane formation have been proposed in several recent 
reviews/publications (Liu et al., 2014; Meng, Wu, Yan, Deng, & Xiang, 2013; Moss, 2015). The 
premise in these models is that there are constant breaks generated in the ER. Although the exact 
manner of how the breaks in the ER are generated remains unclear, it is suggested that, as shown 
in Figure 2.1 (Liu et al., 2014), in the viral infection, L2 associates with the ER membrane and 
recruits the ER membrane segments to the viral factory, then L2 interacts with A30.5 (a protein 
that co-localize with ER and L2 but is synthesized after the DNA replication.) and A11 (a protein 
that is expressed late in the infection and is only localized in the viral factories.) or possibly some 
other unidentified proteins to stabilize the ER membrane segments by capping the free end of the 
segments. The structural viral membrane proteins D13, A17 and A14 are detected on the ER 
segments in the viral factories. They are thought to interact with each other and serve as precursor 
for elongating the segments to form crescents and spherical immature virions by fusion with 
additional ER membrane segments. However, further studies are needed to attest and complete 
the above assumptions. 
 
Figure 2.1 Model of Vaccinia virus crescent membrane formation 
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Among all the VMAPs, the 17k Da H7 protein is the focus of this study. Previous mutant 
deletion studies demonstrated that H7 is crucial for crescent membrane and IV formation (Meng 
et al., 2013; Satheshkumar, Weisberg, & Moss, 2009). However, similar to A11, it yet shares no 
sequence homology, H7 does not integrate into the subsequent MV membrane. Also, studies 
showed that H7 localizes not only in viral factories but also throughout the cytoplasm, indicating 
its function is not limited to viral factories (Satheshkumar et al., 2009). Structure –function 
studies previously done by our lab (Kolli et al., 2015) shed some lights into the possible function 
of H7 from a structural perspective.  
In the published paper, the majority of the H7 protein structure has been solved. A 
phosphoinositide-binding site was identified on two regions of the H7 protein, including the C-
terminal tail and a surface patch that is comprised of basic residues. Through lipid overlay and 
fluorescence polarization-based lipid binding assays, the binding of H7 with phosphoinositides, 
PI3P and PI4P, was confirmed. A model, in which a positively charged pocket for binding 
phosphoinositdes was formed by two regions interacting with each other, the C-terminal’s 
possible function serving as a switch, was proposed from the study. Yet due to the intrinsic 
nature, the 29 residues at the C-terminal tail were not visible in the published H7 structure in the 
absence of lipids.  
In this study, we aim to solve the complete structure of H7 in complex with 
phosphoinositides PI3P and PI4P. Since H7 shares no homologs outside the poxvirus family and 
there is no discernible functional motif identified, the structure-function study of H7 with lipid 










III.1 Protein Expression in E.coli 
Table 1. Buffers and Media Formulation for protein expression in E.coli 
    
  1. 1L LB Media                 2. 1000X IPTG 
5g NaCl                             Dissolve 2.38g IPTG into 10ml ddH20     
5g Yeast Extract              3.1000X Antibiotics 
10g Tryptone                    Kanamycin: 50mg/ml 
Add ddH20 to 1L.             Ampcilin: 100mg/ml 
 
1.Prepare LB media media and autoclave for 45 minutes on liquid cycle. Afterwards, inoculate 
50-100 ml LB media with fresh antibiotic, using glycerol stock cells. Incubate the culture at 30 
°C, 250 rpm overnight as the overnight culture. 
15 
 
2. Spin down the overnight culture using a sterilized tube by centrifugation (Beckman centrifuge), 
3500 rpm for 20 minutes. After the centrifugation, use pipette to gently re-suspend the cell pellet 
in fresh media (use 1:50 dilution factor as 50ml overnight culture can be used for 2 liter large 
scale expression) with fresh antibiotics. Incubate the large scaled cell culture at 37°C, at 250 rpm. 
Monitor cell growth by measuring OD600 using the spectrophotometer. When OD600 reaches 0.6-
0.7, adjust the shaker’s temperature to 18 °C. Allow at least 45 min for the cells to cool down 
completely before inducing. When the OD600 reaches around 1.0, spike 1ml IPTG in to each 1L 
flask to initiate protein overexpression.  Lower the temperature to 18°C and shake at 250 rpm for 
overnight. 
3. Harvest the overnight cell culture by centrifugation at 4000rpm, 30 minutes. After 
centrifugation, transfer the cell pellet into a new, sterilized 50ml falcon tube. If not proceeding to 
the purification step, the cell pellet are stored at -20°C. 
III.2 Protein Purification  
III.2.1 Two-step Ni-Column Purification (For protein with His-tags) 
Table 2. Buffers for protein purification 
 
1.Buffer A: 20mM Tris, 500mM Nacl, 10% glycerol, 20mM Imidazole, pH8.0 
2.Buffer B: 20mM Tris, 500mM Nacl, 10% glycerol, 250mM Imidazole, pH8.0 




1. Add lysozyme to a finial concentration of 0.5mg/ml into Buffer A, Re-suspend the cell pellet 
from the final step of protein expression in buffer A, using 35-50 ml Buffer A per 1 L culture. 
Leave the suspended cell pellet on ice or 4 °C for 40 minutes. 
2. To reduce the viscosity, add DNAase (5mg/ml in ddH20, use 5-10 ul for 50ml lysate) in the cell 
lysate. 
3. Use Cell Homogenizer to further lyse the cells. 
4. Centrifuge (Sorval) the cell lysate at 11,000 rpm, 4 °C for 30 minutes. 
5. Filter the cell supernatant by using a 0.45 um filter. 
6. Pre-equilibrated Ni-NTA resin (Qiagen) buffer A. Incubate the filtered supernatant with Ni-
NTA resin on rocker in the cold room, rocking for 1 hour. (Binding capacity: 1ml resin for 10 mg 
protein.) 
7. Use a 25 ml gravity flow column to collect the Ni-NTA resin, allowing all the liquid to flow 
through. 
8. Wash the resin with 100 ml cold buffer A. 
9. Elute the protein out with 20 ml buffer B and collect the flow in a 50 ml falcon tube. 
10. Measure the protein concentration by Bradrad regent. Add a proper amount of rTEV (Qiagen) 
protease into the protein sample for cleaving the N-terminal 6xHis tag. Use 1:40 molar ratio of 
TEV: protein sample. The Molecular weight of rTEV is around 30KDa. 
11. Put the mixture in a dialysis bag and subject to 1L dialysis buffer at 4 °C in cold room 
overnight. Clean the Ni-NTA column with 50 ml buffer B and then 30 ml buffer A. 
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12. Equilibrate the Ni-NTA column from previous steps with 30 ml dialysis buffer. Filter the 
dialyzed protein sample with 0.45 um filter and let it flow through the column 3 times by gravity 
flow. Collect the flow through. This is the purified protein. Run SDS-PAGE gel for protein 
analysis. 
III.2.2 Size Exclusion Chromatography 
To further purify the target protein after Ni-Column purification, use AKTA HPLC system (GE 
Health) and highload 16/600 superdex 75 column (GE Health) to separate the target protein from 
impurity based on the difference of molecular sizes. Generally, the higher the molecular weight of 
the protein, the earlier the peak appears on the chromatography. 
III.2.3 Ion Exchange Chromatography 




Use AKTA HPLC system (GE Health) and Q sepharose column (GE Health) to separate 
molecular base on their different binding affinity with the column under a certain pH and with a 
gradient salt concentration. 
III.2.4 High Pressure Chromatography 
Use AKTA HPLC system (GE Health) and s200 high-pressure column (GE Health) to separate 
molecular with a higher resolution. 
III.3 Protein Concentration Assay 
Buffer A: 50mM Nacl, 20mM Tris, pH 8.0 
Buffer B: 1M Nacl, 20mM Tris, pH8.0 
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Use the Bio-Rad protein assay kit (Life research). The detailed steps refer to the product 
instruction online. 
III.4 Lipid Overlay Assay 
1. Block the PIP strip (Echelon Biosciences) in 10ml 3% BSA, TBS-T (Tris buffered saline and 
Tween 20) for 1 hour at room temperature, shake gently during the blocking. 
2. Discard the blocking buffer from step1, add protein of interest into 3% BSA, at final 
concentration of 1ug/ml, incubate with the PIP strip for 1 hour at room temperature, shake gently 
during the incubation. 
3. Discard the solution from step2, wash the PIP sheet with TBST, 5ml, 5 minute each time, 6 
times. 
4. Incubate the PIP sheet with mouse polyclonal anti-H7 antibodies (provided by Dr.Xiang from 
UTHSCSA) at 1:1000 ratio at room temperature for 1 hour. 
5. Wash the PIP sheet as in step3. 
6.Incubate the PIP sheet with anti mouse secondary HPR antibody at 1:2000 ratio at room 
temperature for 1 hour. 
7. Wash the PIP sheet as in step3. 
8. The signal was detected by chemiluminescence (West Pico by Thermo Scientific).  
III.5 Crystallization 
Sitting-drops method was used for the crystallization. Crystallization screening plates were set up 
manually or by Gryphon LCP (Art Robins Instrument) with 0.5ul protein+0.5ul screening buffer 
in the well and 50ul screening buffer in the reservoir, at both room temperature and 4 degree. 
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The 96-well commercial crystallization screens used in the study are listed in Table 7. 










For the H7 lipid complex, lipid PI3P and PI4P are prepared in 50mM Hepes, pH 7.0 buffer at 
10mM stock concentration. In the complex, the lipid final concentration is 1mM. Thus, 45ul 
H7+5ul lipid stock, incubate in cold room for 1 hour.  When adding lipid and protein together, 
add lipid first to avoid local high concentration. 
Screen                                                  Manufacturer 
PEG/Ion (I/II)                                    Hampton Research 
Index                                                  Hampton Research 
WIZARD (I/II/III/IV)                        Rigaku Reagent 
Crystal                                                Hampton Research 
JCSG Core (I/II/III/IV)                      Qiagen 
NATRIX                                            Hampton Research 








III.1 H7 Construct Sequence Information 
III.1.1 H7 BamB Construct Sequence Information 
Apo H7 crystals diffracted to about 2.7Å resolution. In order to explore different crystal forms of 
H7 that offer better resolution, we used a fusion strategy to clone H7 into a modified pET vector 
containing E.coli BamB gene (Jansen, Baker, & Sousa, 2015) with a N-terminal removable His 
tag. Two different linkers between BamB and H7 were designed giving PBO99: N-His- (TEV 
site)-BamB-G-S-H7, and PBO100: N-His- (TEV site)-BamB-G-S-G-S-H7. The rationale was 





PBO99: N-His- (TEV site)-BamB-G-S-H7
 
The 6XHis tag is labeled by the dot, the green dash line labels the BamB protein, while the ‘star’ 
indicates the G-S linker, H7 protein itself is indicated by the straight line.
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PBO100: N-His- (TEV site)-BamB-G-S-G-S-H7 
  
The 6XHis tag is labeled by the dot, the green dash line labels the BamB protein, while the ‘star’ 
indicates the G-S-G-S linker, H7 protein itself is indicated by the orange straight line.
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H7 BamB constructs are started with a 6-His tag following with a TEV enzyme site. A BamB 
protein was fused to the H7 protein with a G-S (for PBO99 construct) or G-S-G-S (for PBO 100 
construct). The isoelectric point (PI) and molecular weight (MW) for both constructs with and 
without His tag are summarized in the Table 5 below.  
Tabel 5. H7 BamB constructs PI and MW 
 Theoretical pI  MW 
99:N-His-BamB-GS-H7 5.28  58.6 
100:N-His-BamB-GSGS-H7 5.3 59 
99:BamB-GS-H7 5.08  56 
100:BamB-GSGS-H7 5.08  56 
BamB 4.73 39 
 
III.1.2 H7 Sumo Construct Sequence Information 
In parallel, we hypothesized that lipid binding with H7 could stabilize its flexible C-terminal tail, 
generating high-resolution diffracting crystals. Therefore, we continued to purify the Apo H7 






H7-SUMO construct: N-His-SUMO-H7 
 
H7 SUMO construct starts with a 6-His-SUMO moiety followed with the sequence of H7. The 
long dash line labels the His-SUMO, while the dots label the ULP1 enzymatic site, the orange 
straight line labels the H7 protein itself. The isoelectric point (PI) and molecular weight (MW) for 
the H7 SUMO constructs with and without His tag are summarized in the Table 6 below
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Tabel 6. H7 SUMO construct PI and MW 
 
 
III.2 H7 Construct Expression and Purification 
III.2.1 H7 BamB Construct Expression and Purification 
The H7 BamB constructs were expressed with 0.2mM IPTG induction at 18oC overnight. A 2-
step Ni-NTA affinity purification was applied for the initial purification. The first Ni-NTA 
purification step captures his-tagged BamB-H7 fusion. After TEV cleavage of the his-tag moiety, 
the untagged BamB-H7 fusion was applied on the 2nd subtracting Ni-NTA column and collected 
as flow through (Fig. 3.1). The expression and Ni-NTA purification protein samples were 
collected at each step for a SDS-PAGE gel analysis. The result is presented as follows: 
  






(The lanes from left to right indicate: protein marker, non-induce sample, IPTG induced sample, 
cell lysate flown through Ni-NTA resin, 1st buffer A elution, 1st buffer B elution,)  
The final product that contains the target protein BamB-H7 is majorly in 2nd FT section. 
After 2nd Ni-NTA purification, protein concentration for: 
PBO99 (H7 BamB with a shorter linker) is 2.5mg/ml, total: 25-30mg, the productivity for this 
construct is around 15mg/L in E.coli. 
PBO100 (H7 BamB with a longer linker) is 2.7mg/ml., total: 25-30mg, the productivity for this 
construct is around 15mg/L in E.coli. 
After the two- step Ni-NTA purification, the 2nd FT section sample was collected and 
concentrated for further purification by Highload 75 column in AKTA HPLC equipment. The 
purification chromatography is as followed. 
 
Figure 3.2 Gel filtration chromatography of H7 BamB on superdex hi-load 75 column 
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To verify the proteins contained in each peak, a 10% SDS-PAGE gel was applied. The result of 
the SDS-PAGE gel is as follows: 
 
 
Figure 3.3 SDS-PAGE analysis of H7 BamB from fractions of gel filtration 
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(“M” refers to the protein marker; Fraction 22 to27 refers to leftist peak, fraction 28 to 32 refers 
to the middle peak and fraction 33 to 38 refers to the rightest peak) 
From the SDS-PAGE gel’s result on the H7 BamB construct’s Highload 75 chromatography, we 
collected fraction 29 to 32 which bands molecular weight are close to 56 k Da to do some further 
purification by high pressure column s200. One of the results (since all of the fraction runs have 
the same chromatography, here only present one as an example.) from the high-pressure s200 
analytics column is as follows: 
 
Figure 3.4 H7 BamB construct high-pressure column chromatography.To verify the contents of 
the peak appeared on the chromatography, a 10% SDS-PAGE gel was applied. The SDS-PAGE 
gel result on this is presenting as follows:  
U
V






Figure3.5 SDS-PAGE analysis of H7 BamB collected from gel filtration chromatography using 
high-pressure s200 column. 
("M” refers to the protein marker; Fraction 28 to 31 refers to the peak on the high pressure s200 
column chromatography. ) 
From the SDS-PAGE gel’s result on the the H7 BamB construct High-pressure 200 column 
chromatography, we collected all the fractions that only contains one single band with the 
molecular weight around 56k Da to concentrate them to a saturation point and ready for 
crystalllizatioon set up. 
To verify the pufity of the protein sample after concentration, a 10% SDS-PAGE gel was applied. 
The final product that used for crystallization on the SDS-PAGE gel is presenting as followed: 
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Figure 3.6 SDS-PAGE analysis of H7 BamB final product. 
(“M” refers to the protein marker.) 
The purified H7 BamB protein was concentrated to around 10mg/ml in 20 mM Tris, 50mM Nacl, 




III.2.2 H7 SUMO Construct Expression and Purification 
The H7 SUMO constructs were expressed with 0.2mM IPTG induction at 18oC overnight. A 2-
step Ni-NTA purification strategy was used for the initial purification as described in III.2.1. 
Protein samples along the expression and Ni-NTA purification steps were collected and analyzed 




Figure3.7 4-Litter H7 SUMO construct expression and 2-Step Ni-NTA purification. 
("M” refers to protein marker; “FT” refers to flow through sample; “EA” refers to buffer A 
elution sample; “OD” refers to overnight dialysis sample; “EB” refers to buffer B elution 
sample.) 
From the SDS-PAGE gel’s result, we collected sample from the 2nd FT to do further purification. 
High-load 75 column in AKTA HPLC equipment was used for the further purification, with the 




Figure 3.8 Gel filtration chromatograph of FL H7 using high-load superdex 75 column 
To verify the proteins contained in each peak, a 15% SDS-PAGE gel was applied. The result of 
the SDS-PAGE gel is as followed: 
 
Figure 3.9 SDS-PAGE analysis of the fractions collected from gel filtration.  
(“M” refers to the protein marker; Fraction 23 to 24 refers to the far left peak; Fraction 30 to 31 
refers to the middle peak; Fraction 35 to 40 refers to the far right peak.) 
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From the SDS-PAGE gel’s result on the H7 SUMO construct’s Highload 75 chromatography, we 
collected fraction 35 to 40 of which bands molecular weight are close to 17 k Da to do some 
further purification by ion exchange purification.  Considering the H7 protein and SUMO 
protein’s PI, a sepharose Q anion exchange column was used with Tris-buffer at pH 8.0. The 
result from the Q column ion exchange purification is shown in Fig. 3.10.  
Figure 3.10 Ion exchange purification of FL H7 
From the ion exchange chromatography, there are majorly two peaks appeared. The first peak that 
appears was the flow-through peak containing samples that did not bind with the ion exchange 
column. The second peak that followed the first peak contains proteins that eluted with the 
gradually increasing salt concentration. To verify the contents of the peak appeared on the 
chromatography, a 15% SDS-PAGE gel was applied. The SDS-PAGE gel result on this is 
presenting as followed: 
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Figure 3.11 SDS-PAGE analysis of H7 protein from ion exchange chromatography. 
(“M refers to the protein marker”; “FT” refers to flow through which is the far left peak appeared 
on the chromatography; Fraction 4 to 11 refers to the second peak appeared on the 
chromatography) 
From the 15% SDS-PAGE gel analysis on the Q column purification of H7, it is noticed that FT 
sample contains the target protein --H7. The purified H7 protein was concentrated to around 
16mg/ml in 20 mM Tris, 50mM NaCl, flash frozen in LN2 and stored at -80 °C until usage for 
crystallization and lipid binding overlay assay. SDS-PAGE was used to test the purity of the final 
product. The result is presenting as followed: 
 
Figure 3.12 SDS-PAGE analysis of H7 final product. 
(“M” refers to the protein marker;) 
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III.3 Lipid Overlay Assay 
III.3.1 BamB-H7 with Lipids 
Purified BamB-H7 protein was diluted to 1ug/ml in 3% BSA, TBST buffer for the lipid overlay 
assay. The 1st anti-mouse polyclone antibody was used at 1:1000 dilution ratios. The 2nd anti-
mouse HRP conjugated antibody was used at 1:2000 dilution ratios. The result of the lipid 
overlay assay using BamB-H7 fusion is presented in Fig. 3.13. 
 
 























100-pmol spots of 15 different lipids are spotted on certain places at the nitrocellulous strip .The 
light spots in Figure 3.13 are the lipid- bound H7 protein detected by chemiluminescence with 
anti-H7 antibody.  
It shows from the lipid overlay assay that the BamB-H7 binds with PI3P, PI4P, PI5P and 
PI(3,5)P2. 
III.3.2 FL H7 with Lipids 
The lipid-binding assay was carried out in the same way as described above in III.3.1. 
 
 
Figure 3.14 Lipid overlay assay of H7 full length 
Comparing the membrane with the template provided by the company, H7 binds with 
PI3P,PI4P,PI5P,PI(3,5)P2 and PA. Note the lipid binding result is not exactly the same comparing 


























III.4 Crystallization of H7 with Lipids 
From the lipid overlay assay, the PI3P and PI4P’s binding result is consistence with the previous 
studies (Kolli et al., 2015). Thus, at this stage, PI3P and PI4P were used to set up the H7-lipid co-
crystallization for both purified FLH7 and BamB-H7 fusion proteins. 
Among all the screening conditions (listed in Table 4), needle-like crystals from H7-PI3P 
complex formed in: 
 
Figure 3.15 H7-PI3P complex crystal in H11, PEG/Ion II 




Figure 3.16 H7-PI3P complex crystal in H12, PEG/Ion II 
1% w/v Tryptone, 0.05M HEPEs sodium pH 7.0, 20% w/v polyethylene glycol 3,350. 
 
Figure 3.17 H7-PI3P complex crystal in H5, PEG/Ion II 




Figure 3.18 H7-PI3P complex crystal in G11, PEG/ION II 












In this study, both H7’s BamB and Sumo constructs have been successfully expressed 
and purified to homogeneous status. 
  The BamB-H7 construct’s final product is BamB-H7 fusion protein. BamB is part of the 
outer membrane protein assembly Bam complex (Jansen et al., 2015; Wu et al., 2005), which 
crystallized in multiple forms. We hypothesized the fusion of BamB-H7 will yield various 
crystals forms, some of which may diffract to higher resolution.  To exclude the possibility that 
the BamB moiety might block the lipid-binding site on H7, lipid-binding assay was conducted. 
The result of the BamB-H7 lipid binding assay shows that BamB-H7 indeed binds with several 
lipids including PI3P, PI4P, P15P and PI(3,5)P. The intensities of the spots on the PIP sheet 
correlate with binding affinity. It seems like that BamB-H7 has binds stronger with PI3P and 
PI5P. To verify this result, more repetitive experiments on this need to be carry out in the future. 
The H7 SUMO construct’s final product used for setting up crystallization is H7 itself. In 




This SUMO construct was also used in the previous study(Kolli et al., 2015) to solve the 
crystal structure of H7 itself. It was also mentioned in the published paper that H7 used in solving 
the structure is a mutant with a C to S mutation at the position of the 89th amino acid. The mutant 
was used to disrupt the non-specific intermolecular disulfide bond thus improving the quality of 
the crystal. In this study, we used this construct to form a lipid complex for crystallization aim to 
solve the complete structure of H7.One thing caught our notice of this construct is that, the lipid 
binding assay had some different outputs from the published data (Kolli et al., 2015). Except PI3P 
and PI4P, a few other lipids also showed binding affinity in this study. This various unspecific 
binding specificity might due to the 3% BSA blocking buffer used in this study was not fatty acid 
free, which in some cases, might cause different binding pattern. Also, when using 
chemiluminescent method in the final detect step, exposure time also contributes to various out 
put. To verify the lipid binding result, more experiments with optimized buffer and exposure time 
at the last detect step need to be conducted in the future. 
The needle-like crystals formed in this study need further optimization for better crystals 
before proceeding to the X-ray crystallography. 
  The structure-function study of H7 with lipid will verify the model proposed in our 
previous published paper (Kolli et al., 2015) and can provide us more clues in understanding the 
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